Dermavant Sciences

18 articles with Dermavant Sciences

• Dermavant Sciences Announces First Patient Dosed in PSOARING, its Pivotal Phase 3 Clinical Program for Tapinarof for the Topical Treatment of Plaque Psoriasis

  6/5/2019

  Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that the first patient has been dosed in its pivotal Phase 3 psoriasis clinical program, PSOARING, for its lead product candidate, tapinarof. Tapinarof is a therapeutic aryl hydrocarbon receptor modulating agent (TAMA) topical cream being developed by Dermavant for plaque psoriasis and atopic dermatitis

• Dermavant Sciences Appoints Timothy S. Nelson and Kenneth E. Ludlum to Board of Directors

  5/15/2019

  Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that Timothy S. Nelson and Kenneth E. Ludlum have been appointed to Dermavant’s Board of Directors.

• 

  BioSpace Movers and Shakers: March 29

  3/29/2019

  Biotech and pharma companies bring on new talent to strengthen leadership teams and boards.

• Dermavant Sciences Announces Appointment of Cyril Allouche as Chief Financial Officer and Provides Recent Corporate Update

  3/27/2019

  Allouche has over 20 years of combined experience in finance leadership, audit, and advisory roles, most recently serving as Principal Accounting Officer, Head of Finance, and Corporate Controller at Revance Therapeutics

• 

  BioSpace Movers and Shakers: Jan. 4

  1/4/2019

  Biopharma companies begin 2019 with a flurry of hiring to fill executive leadership spots, including Dermavant, UroGen, Melinta, Translate Bio, and more.

• Dermavant Sciences Announces Appointment of Dr. Philip M. Brown as Chief Medical Officer

  1/2/2019

  Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced the appointment of Philip M. Brown, M.D., J.D., as Chief Medical Officer.

• Dermavant Sciences to Present New Data on Cerdulatinib for Atopic Dermatitis and Vitiligo at the 3rd Annual Inflammatory Skin Disease Summit

  12/6/2018

  Dermavant Sciences today announced that the company will present new data on cerdulatinib during the 3rd Annual Inflammatory Skin Disease Summit (ISDS) taking place Dec. 12-15, 2018, in Vienna, Austria.

• 

  BioSpace Movers and Shakers for Nov. 19

  11/19/2018

  Companies bolstered their leadership with additions to boards of directors and c-suite offices.

• Dermavant Appoints Todd Zavodnick as Chief Executive Officer

  11/15/2018

  Mr. Zavodnick has over 20 years of leadership experience in the biopharmaceutical industry.

• 

  Movers and Shakers for Sept. 10

  9/10/2018

  Let's take a look at who made a splash in the pharma and biotech world the past week.
• 

  Celgene Vet Jackie Fouse Taking Over as CEO of Agios Pharmaceuticals; Companies Also Terminate Pr...

  9/5/2018

  One year after stepping down from her role as president and chief operating officer of Celgene, Jacqualyn (Jackie) Fouse has taken over the reins of Cambridge, Mass.-based Agios Pharmaceuticals.

• Dermavant Announces Changes to Leadership and Board of Directors

  9/4/2018

  Dr. Jackie Fouse to step down as Executive Chair of Dermavant

• 

  3 of Vivek Ramaswamy’s ‘Vant Companies in the News: Roivant, Dermavant and Urovant

  8/28/2018

  Three of Vivek Ramaswamy’s companies reported activity today including corporate changes, a licensed therapy and investment of $100 million.
• 

  Dermavant Bags GSK Phase III-Ready Psoriasis Treatment in $330 Million Deal

  7/12/2018

  Months after tapping GlaxoSmithKline dermatology division executive David Rubenstein as its new chief scientific officer, Vivek Ramaswamy’s Dermavant Sciences has returned to the pharma giant to acquire a Phase III-ready psoriasis treatment.

• Dermavant to Present at JMP Securities Life Science Conference

  6/19/2018

  Dermavant announced that President and Chief Operating Officer Vince Ippolito will present a corporate overview at the JMP Securities Life Science Conference

• 

  New Sanofi R&D Boss Marks Yet Another High-Profile Industry Executive Change

  4/24/2018

  Sanofi announced that Elias Zerhouni, head of Global Research and Development, is retiring on June 30. The company has appointed John Reed to replace him as of July 1.
• 

  Dermavant Taps Former GSK Executive as CSO, Licenses New Therapy

  4/3/2018

  Dermavant Sciences, a company founded by biotech guru Vivek Ramaswamy, tapped former GlaxoSmithKline dermatology division executive David Rubenstein as its new chief scientific officer.

• Dermavant Expands Pipeline and Strengthens Executive Team with Key Hires

  4/3/2018

  Dermavant Sciences announced that it has expanded its pipeline by in-licensing an investigational drug for the treatment of multi-focal hyperhidrosis.